Company intelligence / Profile preview

Cipher Gene SafeGene

Ownership: Private
Development stage: Other

Overview

Cipher Gene is a precision medicine service vendor specializing in automated genetic data analysis and interpretation. The company collaborates with clinical doctors to improve diagnosis quality, primarily serving pediatric patients with genetic diseases. It has developed an AI-driven platform used by nearly 300 hospitals and clinics across China. There are no direct clinical trial results as the company's main offering is its analytical platform rather than therapeutics.

Therapeutic areas: OncologyRare DiseasesNeurology
Industry: Molecular Diagnostics

Partnerships

Nearly 300 hospitals and clinics in China utilize their services/platform.

Beyond the preview

Go deeper on Cipher Gene SafeGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cipher Gene SafeGene.

Explore the full profile